Mkts

Vistagen Therapeutics, Inc.

NASDAQ: VTGN
$0.20+0.01 (+6.12%)
As of Nov 18, 4:00 PM ET

Key statistics

Day range
0.180.20
52-week range
0.165.14
Today
Open0.19
Previous close0.20
Volume765.4K
Valuation
Market cap8.02M
P/E ratio—
EPS (TTM)-1.68
Income & risk
Dividend / yield—
Beta0.51
Avg volume8.99M
Discussion

VTGN News

Stories mentioning VTGN from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development13,15814,22315,91511,67810,20711,30510,2157,648
Sales General & Admin
Total Operating Expenses17,18719,84920,31116,04814,48015,35414,41012,215
Operating Income (Loss)(16,723)(19,546)(20,053)(15,804)(14,495)(15,120)(14,227)(12,131)
Interest Income
Interest Expense
Other Expense0.006.00(2.00)0.000.000.00
Pretax Income(16,267)(18,899)(19,417)(15,095)(13,635)(14,089)(12,954)(10,733)
Tax Provision7.000.000.000.000.000.007.000.00
Net Income (Loss)(16,274)(18,899)(19,417)(15,095)(13,635)(14,089)(12,961)(10,733)
Earnings Per Share (Basic)(0.43)(0.45)(0.54)(0.47)(0.44)(0.46)(0.42)(0.35)
Earnings Per Share (Diluted)(0.43)(0.45)(0.54)(0.47)(0.44)(0.46)(0.42)(0.35)
Weighted Average Shares Outstanding (Basic)38,07442,23435,74931,93130,87730,71230,63230,603
Weighted Average Shares Outstanding (Diluted)38,07442,23435,74931,93130,87730,71230,63230,603

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About VTGN

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a stock listed on the Nasdaq Stock Market under the ticker symbol VTGN. It last traded at $0.2000 (Nov 18, 2026, 4:00 PM ET), up 6.1% on the day. That gives Vistagen Therapeutics a market capitalisation of $8.0M.

Over the past 52 weeks VTGN has traded between $0.1600 and $5.14.

For the quarter ended Mar 31, 2026 it reported a net loss of $16.3M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$16.3M
Dec 31, 2025—-$18.9M
Sep 30, 2025—-$19.4M
Jun 30, 2025—-$15.1M

From Vistagen Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…